Skip to main content
. 2020 May 15;10:8118. doi: 10.1038/s41598-020-64842-3

Table 2.

Passing rates (i.e., with a dose difference less than 2%) from the point-to-point dose comparisons between the pseudo-CT and reference-CT treatment plans.

Cycle1 Cycle2 Cycle3 Cycle4 Cycle5 Cycle6 Average
Passing rate 95.7% 94.8% 95.8% 96.2% 95.7% 94.2% (95.4 ± 0.7)%